To overcome this limitation, PD-1/PD-L1-targeting peptides can be utilized alongside ICD-inducing agents to synergistically enhance immune activation and inhibit tumor immune evasion mechanisms (Rui et al., 2023). This evidence concerns the gene CD274 and neoplasm.